Summary:
Study to evaluate the cardiovascular safety of Febuxostat and Allopurinol in subjects with Gout and Cardiovascular comorbidities.
Qualified Participants Must:
• If male, be over 50 years of age
•
If female be over 55 years of age and at least 2-years post menopausal
•
The subject has a history of major CV or cerebrovascular disease including at least one of the
following:
» MI
» Hospitalized unstable angina
» Cardiac or cerebrovascular revascularization procedure
» Stroke
» Hospitalized TIA
» Peripheral vascular disease (ankle brachial index ≤0.6, revascularization and/or
well-documented history of claudication)
» History of diabetes mellitus with evidence of micro- or macrovascular disease
(retinopathy, neuropathy, nephropathy, small vessel vascular diseases)
•
Have a history or presence of gout defined as having one or more of the American Rheumatism Association criteria for the diagnosis of gout
Qualified Participants May Receive:
Study medication, study related medical care and may be compensated for time and travel